Lancet Diabetes & Endocrinology

Papers
(The TQCC of Lancet Diabetes & Endocrinology is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Paisan Ruamviboonsuk: saving sight in Thailand857
Vitamin D supplementation and mortality728
Empagliflozin in adults hospitalised with COVID-19: a (null) hypothesis for RECOVERY488
Madelung's disease in a rare 14th century Franco-Flemish woolen tapestry429
Challenges in implementing nationwide epidemiological studies on metabolic non-communicable diseases in low-income and middle-income countries398
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial382
Metabolic non-communicable diseases in India: time to act381
Shahrad Taheri: putting patients' needs first344
Automated insulin delivery during the first 6 months postpartum (AiDAPT): a prespecified extension study320
Food and class: a peculiarly British affair306
Association of glycaemic index and glycaemic load with type 2 diabetes in the PURE study – Authors' reply302
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality299
Current insights and emerging trends in early-onset type 2 diabetes261
Youth-onset type 2 diabetes among First Nations young people in northern Australia: a retrospective, cross-sectional study252
Postsurgical radioiodine ablation in low-risk differentiated thyroid cancer251
Ashley Grossman: finding a calling in neuroendocrinology244
Mark Atkinson: bringing two worlds together242
Vitamin D to prevent acute respiratory infections226
Action framework on healthy food: a way forward for the public sector209
Fetal growth patterns as early markers of fetal programming205
Perfluoroalkyl and polyfluoroalkyl substances: the price of forever chemicals201
Tackling childhood obesity in low-socioeconomic status communities: what is the next step?200
Implications of technology guidelines for low-income and middle-income countries185
Diabetes and the WHO Model List of Essential Medicines171
The human factor169
Insulin for all: a hope yet to be realised159
May Ng: a lifetime commitment to children156
A framework for improving diabetes care in humanitarian emergencies153
Semaglutide for obesity: four STEPs forward, but more to come147
A community-based, multi-level, multi-setting, multi-component intervention to reduce weight gain among low socioeconomic status Latinx children with overweight or obesity: The Stanford GOALS randomis147
Effect of the COVID-19 pandemic on body weight in people at high risk of type 2 diabetes referred to the English NHS Diabetes Prevention Programme143
Big babies, small babies: metformin exposure in pregnancy140
Data processing in the DMagic cluster randomised controlled trial138
People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action138
Milestone achievement for global access to blood glucose meters and test strips137
South Africa to produce insulin for Africa in 2024135
Association of age with gaps in diabetes-related care and hospitalisations from childhood to young adulthood in Quebec, Canada: a cohort study127
Reducing sodium intake: step-by-step targets yield success121
Thought for food: a Cushing's syndrome enigma explained115
Progress in diabetes prevention or epidemiology—or both, or neither?110
Newer antidiabetic agents: at what price will they be cost effective?110
The growing clinical effect of SGLT2 inhibitors107
Mendelian randomisation and vitamin D: the importance of model assumptions106
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes – Authors' reply101
Targeting RET-mutated thyroid and lung cancer in the personalised medicine era101
Banning diabetes blanket bans101
Hot topics on insulin access: the issue of thermostability100
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale100
Anand Hardikar: a scientific nomad searching for the truth99
Gender disparities in publishing: from words to actions98
The food system: hunger for change96
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, p95
Cardiovascular morbidity and mortality in patients in Wales, UK with resistance to thyroid hormone β (RTHβ): a linked-record cohort study94
Associations between reductions in routine care delivery and non-COVID-19-related mortality in people with diabetes in England during the COVID-19 pandemic: a population-based parallel cohort study93
Post-exercise recovery for the endurance athlete with type 1 diabetes: a consensus statement91
What's in a decade?85
Metastases to the thyroid gland: how does this affect cytohistological diagnoses?85
Call for prospective studies of continuous glucose monitoring to define the glycaemic response to bariatric surgery84
GLP1 receptor agonists: from antihyperglycaemic to cardiovascular drugs82
A compass for navigating the perils of hypertriglyceridaemia81
Better testing and labelling of drugs for people with obesity78
Impact of BMI on COVID-19 vaccine effectiveness76
GLP-1 analogue therapy for obesity in people from Asia75
Tirzepatide adds hepatoprotection to its armoury73
Direct-to-consumer services: improving access to care for people with diabetes and obesity73
What's preventing us from curbing the obesity crisis?73
Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records73
Sleep: a neglected public health issue72
Tight versus liberal blood-glucose control in the intensive care unit: special considerations for patients with diabetes72
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes68
Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy o66
Glucose intolerance in pregnancy and risk of early-onset type 2 diabetes: a population-based cohort study66
Singapore's “War on Diabetes”64
Childhood cancer survival: a gap in need of closing64
World Health Assembly ratifies first global diabetes targets63
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial63
Evaluation of a type 2 diabetes remission programme62
Obesity in people living with type 1 diabetes60
Setmelanotide for the treatment of severe early-childhood genetic obesity60
Evaluation of a type 2 diabetes remission programme – Authors' reply59
Dulaglutide for erectile dysfunction in type 2 diabetes59
Setmelanotide: new promise for the treatment of hypothalamic obesity?58
Forecasting therapeutic responses by albuminuria and eGFR slope during the DAPA-CKD trial53
SGLT2 inhibitors in clinical practice52
Measuring serum testosterone in women50
The potential role for artificial intelligence in fracture risk prediction49
Adrenal myelolipomas48
Impact of COVID-19 on diagnoses, monitoring, and mortality in people with type 2 diabetes in the UK48
Associations of the glycaemic index and the glycaemic load with risk of type 2 diabetes in 127 594 people from 20 countries (PURE): a prospective cohort study47
The growing global burden of thyroid cancer overdiagnosis46
Data-driven subgroups of type 2 diabetes, metabolic response, and renal risk profile after bariatric surgery: a retrospective cohort study46
Diabetes and the WHO Model List of Essential Medicines46
Risk and course of SARS-CoV-2 infection in patients treated for hypothyroidism and hyperthyroidism45
Osteopenia: a key target for fracture prevention45
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial44
National UK guidelines for the management of paediatric craniopharyngioma42
Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials42
Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study41
PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial40
Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17)40
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials39
The relevance of T3 in the management of hypothyroidism39
Management of thyroid nodules39
Obesity in the USA: diet and lifestyle key to prevention39
Estimating the total incidence of type 1 diabetes in children and adolescents aged 0–19 years from 1990 to 2050: a global simulation-based analysis39
The effect of monthly vitamin D supplementation on fractures: a tertiary outcome from the population-based, double-blind, randomised, placebo-controlled D-Health trial38
New metrics to support diabetes education and advocacy38
Osteoporosis in men37
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, dou36
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel36
Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study36
Nutritional intake and bone health36
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis35
An anti-PCSK9 pill a day to keep cholesterol away: next steps?35
Sex steroids and the female brain across the lifespan: insights into risk of depression and Alzheimer's disease35
Correction to Lancet Diabetes Endocrinol 2023; 11: 785–8734
Correction to Lancet Diabetes Endocrinol 2021; 9: 743–5433
Correction to Lancet Diabetes Endocrinol 2022; published online Sept 29. https://doi.org/10.1016/S2213-8587(22)00252-232
Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study32
Global diabetes incidence trends in young adults32
Correction to Lancet Diabetes Endocrinol 2022; 10: 741–6032
Disease modifying therapies in diabetes and endocrinology32
Correction to Lancet Diabetes Endocrinol 2023; 11: 942–5432
Correction to Lancet Diabetes Endocrinol 2022; 10: 489–9832
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes32
Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials31
Consensus on diagnosis and management of Cushing's disease: a guideline update31
Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled31
Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study30
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial30
Lifetime risk, life expectancy, and years of life lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based study29
C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis29
Correction to Lancet Diabetes Endocrinol 2022; 10: 58–7428
Iodine deficiency in Europe: vigilance and action required28
Food additive emulsifiers and risk of type 2 diabetes27
Islet-after-kidney transplantation versus kidney alone in kidney transplant recipients with type 1 diabetes (KAIAK): a population-based target trial emulation in France26
Hybrid closed-loop insulin therapy and risk of severe hypoglycaemia and diabetic ketoacidosis in young people (aged 2–20 years) with type 1 diabetes: a population-based study26
Incidence of diabetes after SARS-CoV-2 infection in England and the implications of COVID-19 vaccination: a retrospective cohort study of 16 million people26
Protein-binding therapy: a new approach to lower cholesterol26
Dissection of type 2 diabetes: a genetic perspective26
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions26
Diabetes and the WHO Model List of Essential Medicines25
Nutrition-related health taxes: setting expectations25
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials25
Stigma in type 1 diabetes: a global problem24
Glycaemic management in diabetes: old and new approaches24
Lorenz Hofbauer: connecting the unexpected24
Challenges in the treatment of young people with type 2 diabetes24
Jennifer Manne-Goehler: at the crossroads of pandemics24
Out on a limb: living with diabetes in the Philippines during the pandemic23
Sylvia Kehlenbrink: facing the extremes23
The double burden of poor diets23
New clarity for managing statin intolerance in diabetes23
National registries as a catalyst to development of diabetes care in low-income and middle-income countries23
Prioritising COVID-19 over everything: the unintended harm23
There is no magic bullet for obesity22
Revisiting osteoporosis guidelines22
Explaining the high rate of progression from prediabetes to type 2 diabetes in China22
Challenging diabetes stigma starts and ends with all of us22
The uncomfortable truth about kidney disease in type 1 diabetes22
The TRAVERSE trial: cardiovascular safety of testosterone therapy for older men22
Black oesophagus in an adolescent with type 2 diabetes22
The role of nurses in diabetes care: challenges and opportunities22
Global thyroid estimates in 202022
Association of glycaemic index and glycaemic load with type 2 diabetes in the PURE study21
Jonathan Valabhji: from clinical practice to policy making and back21
The deep pockets of health-harming industries21
Dianna Magliano: at the forefront of change21
Precision nutrition: a step too far?21
Biodiversity and its double-edged role in the pathogenesis of type 1 diabetes20
Silver Bahendeka: the obligation to hope20
SARS-CoV-2 and type 1 diabetes in children in Finland: an observational study19
The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 202019
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study19
Rising diabetes diagnosis in long COVID19
Semaglutide: weighing up the benefits and risks19
Understanding diabetes heterogeneity: key steps towards precision medicine in diabetes19
Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history18
Correction to Lancet Diabetes Endocrinol 2022; 10: 859–6818
Correction to Lancet Diabetes Endocrinol 2023; 11: 798–81018
Correction to Lancet Diabetes Endocrinol 2024; published online Nov 12. https://doi.org/10.1016/S2213-8587(24)00283-318
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial18
Correction to Lancet Diabetes Endocrinol 2023; 11: 75–7618
Gestational diabetes in Australia: navigating a tsunami17
The fight to put food on the table: from past to present17
Obesity: what's in a word?17
Behind the scenes: epigenetic mechanisms rule the roost in pubertal timing17
Metabolic non-communicable diseases in India: time to act – Authors' reply16
Iodine status in Iran: from deficient to replete16
Vitamin D and respiratory infections16
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial – Authors' reply16
Improving health equity through data collection16
Can non-equilibrium thermodynamics explain skeletal muscle insulin resistance due to low mitochondrial content?15
COP27 Climate Change Conference: urgent action needed for Africa and the world15
Youth gender services: a new model for regional care15
Glycaemic index as part of the diabetes prevention strategy14
Enteroviruses and risk of islet autoimmunity or type 1 diabetes: systematic review and meta-analysis of controlled observational studies detecting viral nucleic acids and proteins14
Food additive emulsifiers: a new risk factor for type 2 diabetes?14
Maria Fleseriu: driving excellence in pituitary care14
Type 1 diabetes: heterogeneity in heritability14
An inter-humanitarian agency study of diabetes care and surveillance in humanitarian settings14
Association between BMI and COVID-19 on hospital budgets14
The Human Insulin Thermal Solution project—a private sector initiative to address the thermostability of insulin14
Principles for virtual health care to deliver real equity in diabetes14
Lebanon: insulin out of reach after subsidies lifted13
Definition and diagnostic criteria of clinical obesity13
Achieving replicable subphenotypes of adult-onset diabetes13
0.12508702278137